Tarsus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 15, 2021, details the results of Tarsus Pharmaceuticals, Inc.'s Annual Meeting of Stockholders. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "TARS". The report covers events occurring on June 15, 2021, with a record date of April 19, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
At the Annual Meeting, 14,779,289 shares were present, constituting a quorum out of 20,703,852 shares outstanding. Two proposals were submitted and approved:
- Election of Directors: Two Class I directors were elected to serve until the 2024 annual meeting.
- William J. Link, Ph.D.: 10,943,583 votes for; 393,838 votes withheld.
- Jason Tester: 11,178,808 votes for; 158,613 votes withheld.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 14,778,223
- Votes Against: 50
- Abstain: 1,016
Existing directors Michael Ackermann, Bobak Azamian, Bhaskar Chaudhuri, Andrew Goldberg, and Wendy Yarno will continue to serve until their respective terms expire.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote outcomes.
Key Facts for Investor Verification
- Confirmation of the new Class I director terms extending to the 2024 annual meeting.
- Verification of the continued engagement of Ernst & Young LLP as the independent auditor.
- Review of the definitive proxy statement filed on April 30, 2021, for detailed background on the nominees and proposals.
- Assessment of the high level of broker non-votes (3,441,868) relative to the total shares outstanding.